Moving Targets: Fighting Resistance in Infections, Cancers, Pests
Experiences dealing with resistance in one area of biology can provide insights in others
Shannon E. Greene and Ann Reid
Antibiotics, antivirals, herbicides, insecticides, and anticancer drugs might seem to have little in common. However, each serves a similar purpose. Whether to cure a disease, control an insect that spreads disease, or reduce crop losses, they weaken or eliminate a living entity that is harming humans or their enterprises. The deployment of antibiotics, anticancer drugs, insecticides, and other selective chemical agents has had enormous health and economic benefıts; not for nothing were early antibiotics called "miracle drugs."
However, in every case, these "miracle" treatments come up against a hard truth. Given time and opportunity, the organisms we seek to control will develop resistance to the agents deployed against them. Resistance is not a new phenomenon, and it did not arise solely because of human interventions. Antibiotic resistance in bacteria, for instance, arose as a means for competing species to dominate one another within ecological niches. Mechanisms of resistance in nature range broadly and include the degradation of toxic compounds, expulsion of antibiotics or other drugs from cells, or changes to the drug's cellular target sites such that the target can continue to function despite the presence of the antibiotics or other drugs.
Each of these cases depends on the same fundamental process-cells adapting to survive contact with an otherwise deadly compound. The process is at work when bacterial pathogens evolve resistance to antibiotics and viruses to antiviral drugs, when insects become resistant to insecticides, and when cancer cells stop responding to anticancer agents. Although the underlying phenomenon may be the same, scientists who develop and deploy this broad array of agents do not see themselves as belonging to a single scientifıc community and thus rarely get a chance to learn from one another.
How Does Resistance Evolve and Spread?
The emergence of resistance provides a straightforward illustration of evolutionary selective pressure at work. When a population is subject to a treatment designed to eliminate it, any individuals possessing a trait that mitigates the negative effects are able to proliferate and eventually become dominant. At that point, the treatment is no longer effective at controlling the target population.
The odds of a resistance trait preexisting in a population depends heavily on genetic diversitythe greater the diversity, the greater the likelihood that a variant with some degree of resistance already exists in the population. If resistance is not already present, the odds that it will evolve depend on the genetic "flexibility" of that population. A population's capacity for generating genetic diversity depends on its size, generation time, and mutation rate. Population size posi-tively correlates with diversity and, therefore, the probability of resistance emerging.
Infectious agents, cancer cells, insects, and weeds display a wide range of generation times and mutation rates (Fig. 1) . Some bacterial species, such as Staphylococcus aureus, will undergo cell division every 30 to 60 minutes, whereas mosquitos have a two-week lifespan. Organisms with shorter generation times can develop resistance more quickly than those with longer gener-
FIGURE 1
The emergence and spread of resistance varies across biological systems and depends on key traits of those systems. (A) The speed at which resistance evolves positively correlates with mutation rate and rate of reproduction. A pathogen or pest with a high mutation rate that reproduces quickly, such as HIV or E. coli, will evolve resistance on a much swifter time scale than pigweed, for example, which mutates about three orders of magnitude less frequently and also only reproduces annually. (B) However, once resistance has evolved in a population, its spread is influenced by the number of progeny produced and how far those progeny can disperse, either in terms of distance or individuals infected. A drug-resistant cancer cannot spread beyond its immediate human host. While pigweed may develop resistance more slowly than HIV, the ability of its thousands of seeds to disperse distances of hundreds to thousands of miles makes resistance spread a real threat. Increased globalization plays a significant role in the spread of resistant pathogens; malaria-laden mosquitos may only travel a distance of 100m from where they hatched, but infected humans can bring resistant strains to naïve populations. Indeed, in cases of multi-drug resistant tuberculosis, quarantine is the most viable option for preventing resistance spread. ation times. Viruses such as HIV and influenza not only replicate quickly, but their enzymes responsible for replicating their respective genomes are notoriously error prone, leading to very high mutation rates, on the order of 10 Ϫ5 , which effectively translates to about one mutation per genome replication. Many viruses also generate sequence diversity through recombination or reassortment during replication. Mutation rates among bacteria are orders of magnitude lower, and in eukaryotes that rate drops lower still, ranging from 10 Ϫ11 to 10
Ϫ20
. Moreover, mutation is not the only source of genetic variability. Bacteria can share entire sets of resistance genes through horizontal gene transfer. Additionally, sexual reproduction in fungi, insects, and plants provides another means for genetic variation.
The molecular mechanisms by which resistance can arise are often shared among very different biological species. Resistance can occur through point mutations: discrete substitutions, deletions, or insertions in the genetic code. In some instances, a single point mutation can engender resistance. In other cases, several mutations may be needed. For instance, Plasmodium falciparum, one of several parasites responsible for causing malaria, acquired seven mutations before it became resistant to the drug chloroquine.
Gene amplifıcation is another resistance mechanism, one that is associated primarily with cancer, but also accounts for pesticide resistance among insects and drug resistance among fungal pathogens. Through this mechanism, the organism or cells increase the overall copy number of the target gene such that suffıcient amounts of the encoded protein are available to complete the biological task, despite some of that protein being hindered by the drug or pesticide. Genes encoding detoxifying enzymes may also be amplifıed as a way of conferring resistance to drugs or pesticides. Amplifıed genes can be found scattered throughout genomes, and little is known about the mechanism underlying this mode of resistance. Further, it is not known whether particular organisms are better able to amplify genetic material than others, or whether amplifıcation is specifıc to particular genomic regions or features.
Pests, pathogens, and cancer cells can adapt to otherwise toxic compounds by metabolizing them or by pumping toxins from cells through efflux channels. Drug sequestration is another effective means to achieve resistance. For example, some cancers develop resistance to the antiangiogenic tyrosine kinase inhibitor sunitinib by accumulating the drug inside lysosomes.
Additionally, target organisms can physically avoid the drug or pesticide. Viruses and bacteria can enter latent phases in which they do not replicate, effectively hiding from immune system responses and therapeutic drugs. Many types of bacteria can grow in dense communities called biofılms, which sometimes contain multiple species, and the interior environments of these biofılms are exposed to reduced concentrations of antibiotics. Similarly, cancerous cells within a tumor respond differently to drugs or other treatments than do their counterparts along the boundaries. Understanding three-dimensional tumor "ecology" will be an important development in oncology and in the exploration of drug resistance in cancer.
Although the ways in which pests and pathogens develop resistance to treatment vary widely, signifıcant overlaps and similarities are found across biological systems, including plants, cancers in humans and other mammals, insects, and bacteria and viruses. Because such different biological systems experience similar types of resistance at the molecular and cellular levels, strategies for counteracting those resistance mechanisms might also have features in common.
Designing Treatments with Resistance in Mind
Evolutionary principles were too often neglected when scientists sought to overwhelm biology with chemistry in an onslaught of new drugs and pesticides. Thus, their failure to anticipate that organisms would develop resistance to antibiotic or anticancer treatments as well as to pesticides led to other, longer-term consequences. While it may be impossible to prevent resistance, some treatment strategies might postpone the inevitable because they prove more diffıcult for the target organisms to "evolve around."
One important bit of advice is to make drugs or other agents that are specifıc. Thus, drawing upon structural, enzymatic, and sequence information about particular targets, it makes sense to design chemical agents to disrupt specifıc and essential features. Resistance seems more likely to arise if drugs interact with flexible targets. For instance, several triazine herbicides target the D1 In contrast, a newer anticancer agent, imantinib, which is being used to treat chronic myeloid leukemia, targets the bcr-abl fusion protein generated from the specifıc chromosomal translocation that instigates this disease. Although resistance eventually develops, it is almost always by the same, predictable mutation, which made it possible to develop a specifıc secondary drug that can be administered as soon as resistance is detected.
Another important piece of advice is to choose the right target. For example, the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D), which mimics the essential plant signaling molecule auxin, has been used widely for more than 70 years. This synthetic chemical agent works so well because it interferes with the extensive network of binding partners of auxin. If plants develop resistance to 2,4-D, that resistance tends to disrupt native auxin interactions and therefore confers a steep fıtness cost. Hence, resistance to 2,4-D proves to be relatively rare.
Further, if possible, use more than one treatment simultaneously. In 1987, initial efforts to treat HIV proved successful in the short term, but the virus quickly developed resistance to the frontline antiretroviral drug AZT. After the emergence of AZT resistance in a patient, doctors would introduce a second-line therapy, which would continue until secondary resistance evolved. HIV infection management underwent a paradigm shift when reports surfaced of patients prescribed just one antiretroviral drug, but taking another on the side. Indeed, these individuals exhibited undetectable viral loads for much longer than patients treated with a single antiretroviral agent alone. Despite stories of promising HIV treatment surfacing in the mid-1980s, institutional barriers prevented combination therapy from rapid adoption. Persuading regulatory offı-cials to accept combination therapy required demonstrating that each component added benefıt. To demonstrate benefıt, "benefıt" had to be redefıned-in this case, the acceptance by the FDA of viral load as an indicator of disease status in the 1990s. Now, HIV-infected individuals are routinely treated with at least three drugs to reduce viral load and prevent resistance from developing to the drugs in that mix.
Despite increasing evidence of the effıcacy of combination drug therapies, the practice has not been implemented widely beyond patients being treated for HIV or tuberculosis infection. For example, patients with cancers still tend to be treated sequentially with single anticancer drugs, and this practice tends to lead to sequential resistance evolution.
However, in a recent clinical trial, patients with small-cell lung cancer were treated simultaneously with a vaccine targeting p53 and a thirdline chemotherapeutic agent. Neither therapy was particularly effective on its own, but patient survival was greatly increased when the two agents were administered together. This enhancement comes from placing the cancer in an "evolutionary trap." In response to the vaccine targeting p53, the tumors down-regulate p53 expression, but p53 contributes to cell survival in the face of toxic perturbations. Thus, response to one therapy resulted in sensitivity to a second therapy. Despite the success of this particular dual-treatment strategy, the expense in running such clinical trials along with the challenge of fınding multiple targets that are unique to cancer cells are formidable barriers to investigating such combination therapies across the broad range of cancer types.
Yet another piece of advice for those designing novel drug treatments is to enlist ecological principles. Perhaps no approach better highlights the value of using evolutionary principles to design and implement a novel pest control strategy than the development of resistance management strategies for transgenic crops producing Bacillus thuringiensis (Bt) toxins (Fig. 2) . Bt proteins, which are not harmful to humans and most other nontarget organisms, kill many key insect pests. A variety of crop plants, including corn, soy, and cotton, are genetically engineered to produce Bt toxins, which are ingested by insect pests that try to feed on the plants, thus reducing the need for other types of insecticides.
Recognizing that target insects would likely develop resistance to such Bt crops, scientists drew on evolutionary principles to design a strategy for managing-and delaying-that resistance. The key element of that management strategy is to set aside "refuges" containing host plants that do not produce Bt toxins and in which Btsusceptible insect pests can continue to grow. The rare mutant insect adults that emerge from and are resistant to Bt crops then are free to mate with the abundant Bt-susceptible adults that are feeding in the nearby refuges. Because resistance is a recessive trait, the progeny of matings between resistant and susceptible adults remain susceptible to Bt and will continue to die when feeding on Bt crop plants, delaying substantially the emergence of full Bt resistance.
Finally, in terms of advice about any new treat- wild-type population can be maintained nearby with which the resistant insects can mate, the selective pressure is reduced and the number of resistant insects increases at a slower rate. This can be accomplished by the planting of refuges, or fields of non-Bt crops fed upon by target pests, near the engineered crops. While a few resistant insects may remain, the crop losses will ultimately be minimal compared to the alternative scenarios and the spread of resistance will be reduced. The refuge strategy works best with recessive resistance, as illustrated here.
ment, use it wisely. Improper use can drive the development of resistance. For instance, antibiotics are very widely and carelessly used in China, and levels of resistance there are among the highest ever measured. In 2001, 89% of hospital-acquired infections involving S. aureus in China were resistant to standard antibiotics compared with 16% in the United States. Soon after antibiotics came into wide use as therapeutic agents in the United States and other developed countries, the drugs were introduced as additives in feedstock for cattle, chickens, and other livestock. This agricultural practice broadly affects human health. The wide use of vancomycin led to widespread resistance to this important drug, and pathogens such as methicillin-resistant S. aureus (MRSA) are becoming an expanding medical problem. Both of these clinical challenges can be traced in part to the enormous use of antibiotics as additives to livestock feed. To this day, there is no coordinated regulation of antibiotic use, even though the actions of these drugs and paths to the development of resistance are identical regardless of where they are being used.
While resistance to the insecticides used to treat protective mosquito nettings is not yet rampant, this method of malaria control is feared to be facing imminent failure. Currently all such bed nets use similar active ingredients, namely pyrethroid insecticides. These insecticides are also used widely in agriculture and as sprays for homes and other settings, thereby increasing selection pressure on mosquitoes and other insects to develop resistance.
Where To Go from Here
Pathogen, cancer, or pest management strategies inevitably depend on one's goal. Drug design and treatment strategy will be approached differently if the sought-after outcome is to eradicate the pathogen, tumor, or pest rather than if one can settle for maintaining the pathogen, cancer, or pest at a manageable level. If eradication is the only acceptable goal, the useful lifetime of the drug or treatment is likely to be reduced because the selection pressure will be higher from the outset.
In treating patients with cancer or infectious diseases, the priority is survival, which almost always equates with eradicating the infectious agent or the cancer. HIV is a notable exceptioncures are sought but long-term management is widely accepted as a triumph. The agricultural industry is far more likely to adopt a management strategy in dealing with insect pests and weeds. In general, farmers are willing to accept lower yields to extend the lifetime of insecticides and herbicides. Conceivably, adopting management approaches for human infectious diseases beyond HIV may result in better outcomes both in terms of patient lifespan and the slowing of drug resistance.
The development of resistance to drugs or pesticides is an evolutionary phenomenon. Hence, taking selective pressures into account from the outset might enable physicians or farmers to avoid or delay some of the pitfalls that can arise when those forces are not considered during initial treatment plans. Reconceptualizing cancer as a disease as not necessarily to be cured, but to be managed, may help in implementing treatments to minimize drug resistance and prolong life. Treatment strategies in medicine well could improve by incorporating components from agriculture and vice versa. Taking a "management" rather than an "eradication" approach may prove valuable for physicians dealing with some kinds of cancers and infectious diseases. Further gains may be had with a paradigm shift away from sequential drug treatment plans towards combination therapy approaches.
Molecular and genetic analyses are bringing a greater, in-depth understanding of pathogens and cancers, and are leading toward more specifıc means of combating them. Taking into account the ecological roles of those species will greatly enhance the available toolkit. Drug developers can benefıt from considering how different environments might be manipulated or exploited to control disease outbreaks or pest infestations. For example, applying ecological approaches to the complex malaria infection cycle is revealing new points at which to intervene, either within the human host or when it is being carried by mosquitoes, which can be targeted at different stages in their life cycle.
Another ecological factor to consider is the spatial organization of target organisms in specifıc environments. When targets are subjected to different doses of a drug, for example, some will be killed while others may be only slowed or unharmed; these differences affect the rate at which resistance evolves in the survivors. Therefore, deepening our understanding of how biofılm and tumor architecture affects drug dosing A valuable illustrative supplement for lectures and laboratory presentations, this easy-to-use atlas was written for laboratorians, clinicians, students, and anyone interested in the field of diagnostic medical bacteriology.
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